Form PTO-1390-MOD (REV 10-96)	J. S. Department of Commerce Patent and Trademark Office	ATTORNEY'S DOCKET NUMBER 33704-US-PCT						
TRANSMITTAL LETTER TO	THE UNITED STATES	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
DESIGNATED/ELECTED	OFFICE (DO/EO/US)							
CONCERNING A FILING	UNDER 35 U.S.C. 371							
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE 30 March 2005 (30.03.05)	PRIORITY DATE CLAIMED						
PCT/EP2005/003332	31 March 2004 (31.03.04)							
TITLE OF INVENTION NOVEL CO-PRECIPITATE OF AMORPHO	OUS ROSIGLITAZONE							
APPLICANT(S) FOR DO/EO/US								
GREIL ET AL.								
Applicant herewith submits to the United States	Designated/Elected Office (DO/EO/US) t	he following items and other information:						
 This is a SECOND or SUBSEQUENT This express request to begin national examination until the expiration of the A proper Demand for International Predate. A copy of the International Application 	as filed (35 U.S.C. 371(c)(2))	f)) at any time rather than delay b) and PCT Articles 22 and 39(1). 9th month from the earliest claimed priority						
a. is transmitted herewith (required by the Irection of the International Application of the Internation of the International Application of the International Application of the International Application of the Internation of the Internation of the Internation of the Internation of the Internatio	ed only if not transmitted by the Internation ternational Bureau. (See Form PCT/IB/3 tion was filed in the United States Receiving cation into English (35 U.S.C. 371(c)(2)). International Application under PCT Article 19 tired only if not transmitted by the International Bureau. International Bureau. In the time limit for making such amendment to the made.	08) ng Office (RO/US). (35 U.S.C.371(c)(3)). ional Bureau). ents has NOT expired.						
8. A translation of the amendments to th 9. An executed Declaration and Power of 10. A translation of the annexes to the Int 371(c)(5)).	e claims under PCT Article 19 (35 U.S.C. if Attorney (original or copy) (35 U.S.C. 37 ernational Preliminary Examination Repor	′1(c)(4)).						
Items 11. to 16. below concern document(s)	or information included.							
	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.							
12. An assignment document for recording	An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.							
13. A FIRST preliminary amendment. A SECOND or SUBSEQUENT prelim	inary amendment.							
14. An Application Data Sheet under 37 C	CFR 1.76.							
15. A substitute specification.								
16. A change of power of attorney and/or	address letter.							
17. A computer-readable form of the sequ	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.							
18. A second copy of the published Interr	ational Application under 35 U.S.C. 154(c	t)(4).						
19. A second copy of the English language	A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).							

20.

Other items or information: UNEXECUTED DECLARATION

U.S. APPLICATION NO. (if known, see 37	CFR 1.5)	INTERNATIONAL APPLICATION NO. PCT/EP2005/003332			ORNEY'S DOCKET NUMBER 704-US-PCT		
The following fees are submi	tted:					CALCULATIO	NS PTO USE
The following loop and dearm						ONLY	
21. Basic national fee	9				\$300		
22. Examination Fee If International preliminary examination report was prepared by USPTO							
If International pro	eliminary examı isfv provisions c	nation report was pre of PCT Article 33(1)-(pared by USF 4)		\$		
					ድጋበር		
All other situations							
23. Search fee				. .			
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international application to the USPTO as an International Searching Authority\$							
⊠ If International Search Report was prepared and provided to the Office. \$400							
All other situation	S ,	,			\$		
	тот	AL OF 21, 22 AND 2	3 ==		:	\$ 900	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction							
program listing filed in an ele thereof	ectronic medium). The fee is \$250 fo	r each additio	nai 50 sne	ets of paper of	raction	
Total Sheets Extra she		r of each additional to (round up to a whole		!	RATE		
- 100 =	/50 = thereor	(round up to a witon	a ridinber)	X \$	250	\$	
							1
Surcharge of \$130 for furnishmenths from the earliest claim	hing the oath of	declaration later that e (37 CFR 1 492(e))	n 🗌 30			\$	
CLAIMS	NUMBER FILE	D NUMBER	EXTRA		NTE		
Total claims		20 = 0		X \$ X \$	50 200	\$ 400	
Independent claims MULTIPLE DEPENDENT C	Ψ	. 3 = 2 cable)		+ \$	360	\$ 400	
		TOTAL O	F ABOVE (CALCUL	ATIONS =	\$ 1,300	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be					•	***************************************	
filed (Note 37 CFR 1.9, 1.27, 1.28).					\$ \$ 1,300		
Processing fee of \$130 for furnishing the English translation later than 30 months from the					1		
earliest claimed priority date (37 CFR 1.492(f)).				\$			
TOTAL NATIONAL FEE =				\$ 1,300			
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied					\$		
by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property TOTAL FEES ENCLOSED =					\$ 1,300		
					Amount to		
						be: refunded	
						charged	\$
		to cover th					
b. Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1,300 to cover the above fees. A duplicate copy of this form is enclosed.							
c. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to							
Deposit Account No. 19-0134 in the name of Novartis.							
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.							
Send all correspondence to the address associated with							
Customer No. 001095, which is currently:						no	
				D/Thallem			
Novartis Attorpley for Applicants Corporate Intellectual Property Reg. No. 34,940							
One Health Plaza, Building 104 (609) 627-8507							
East Hanover, NJ 0	7936-1080						